Clinical Trials Logo

Clinical Trial Summary

Transthyretin amyloidosis (aTTR) initially described as a rare disease, became the most serious hereditary polyneuropathy of adult onset and family screening has made it possible to identify and follow up many asymptomatic patients and carriers of the mutation in the TTR gene. Considered as a systemic disease with involvement of target organs (the heart, the eye, the kidney and peripheral nervous system), it seems to be more complex for neurologists according to recent publications raising the issue of central nervous system involvement. Indeed, TTR amyloid deposits seem to be correlated with the duration of the disease. These deposits can cause cortical damage by different mechanisms: direct TTR toxicity or as a result of pathology related to cerebral amyloid angiopathy (intraparenchymal or subarachnoid hematomas, small infarcts, hemosiderin). A small number of mutations in the TTR gene cause a rare phenotype of systemic amyloidosis, the oculoleptomeningeal form, characterized by clinical neurological symptoms: progressive dementia, epilepsy, ataxia, spastic paraparesis, stroke-like episodes. Hypothesis of the work: the central nervous system involvement is probably underestimated on the radiological description in patients with TTR mutation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05075798
Study type Observational
Source Centre Hospitalier Universitaire de Nimes
Contact
Status Completed
Phase
Start date October 25, 2021
Completion date May 31, 2022

See also
  Status Clinical Trial Phase
Completed NCT03190577 - Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology N/A
Completed NCT03588468 - Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study N/A
Completed NCT03591757 - Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) Early Phase 1
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Terminated NCT04611204 - Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surgery
Completed NCT03352089 - Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis
Recruiting NCT05814380 - The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis.
Completed NCT03886155 - Cardiac Amyloidosis Screening at Trigger Finger Release
Completed NCT03923920 - Screening for Systemic Amyloidosis Via the Ligamentum Flavum
Completed NCT03862807 - Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant Phase 3
Completed NCT02792790 - Carpal Tunnel Syndrome and Amyloid Cardiomyopathy
Completed NCT03860935 - Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy Phase 3
Not yet recruiting NCT06465810 - Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Recruiting NCT04963985 - The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients Phase 4
Recruiting NCT05409833 - Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population
Recruiting NCT05635045 - Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR Phase 2
Completed NCT01171859 - Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis Phase 2
Recruiting NCT03237494 - TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
Recruiting NCT04899180 - Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis Early Phase 1
Recruiting NCT06345235 - New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis